Research Article

Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis

Table 1

MDS patient demographic and diagnostic data.

AgeSexHctPltsANCBlast %CytogeneticsDiagnosisIPSS
PBMRW

158M38661.700t(1;7)Hypocellular RCMDInt-2
272M24915.504(−5, −7)RCMDInt-2
375F25134.300.51 abnormal cellRCMD-RSInt-1
459M321340.8013(20q-, −5, +14)RAEB-2High

562M28350.90<5(−7)2° MDS, retic fibrInt-2
65F24490.90<0.546XXRCMDInt-1
759M26121.80<0.546XYRCMDInt-1
882F24271.10<5no metaphasesMDS with retic fibrInt-1
965F38972.101.5(−5)RCMDInt-1
1052F213663.503.546XXRCMDLow

1163M30200.8411(−5, −7), otherRAEB-2High
1265F26230.70646XXRAEB-1Int-1
1367F24130.0308(−5, 20q-)RAEB-1Int-2
1458M26660.1012(20q-)RAEB-2Int-2
1564M27510.2011t(3; 21)RAEB-2High

1638F352080.700.546XXRCMDLow
1758M27150.05011(20q-)RAEB-2Int-2
1820M37230.20<0.5(−7) (familial)RCMDInt-2
1981M301783.501.546XYRCMDLow

Hct: % hematocrit; Plts: platelets (thousands/microliter); ANC: absolute neutrophil count (thousands/microliter); PB: peripheral blood; MRW: marrow; retic fibr: reticulin fibrosis; RCMD: refractory cytopenia with multilineage dysplasia; RAEB: refractory anemia with excess blasts; IPSS: International Prognostic Scoring System for MDS; Int: intermediate.